Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
TEMPLE CITY, Calif., Feb. 27, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) today announced that Ming Hsieh, Chairman and Chief Executive Officer, and Paul Kim, Chief Financial Officer, are scheduled to participate in the 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference on Wednesday, March 1, 2017 in Snowbird, Utah.
BTIG’s annual conference consists of a series of one-on-one meetings and will not be webcast.
About Fulgent Genetics
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts: The Blueshirt Group Nicole Borsje, 415-217-2633, [email protected] Chris Danne, 415-217-5865, [email protected]
